Review Article Environmental Health Integrative/Complementary Medicine
Tranexamic acid and in-hospital mortality in adults with type 2 diabetes: A case series

Tranexamic acid and in-hospital mortality in adults with type 2 diabetes: A case series

Authors

Yusuf Silva

Yusuf Silva

Cleveland Clinic Abu Dhabi, Iceland

Corresponding
Layla Volkov

Layla Volkov

Singapore General Hospital, Bangladesh

Published

March 21, 2025

Paper ID

PAP-000161

Status

Published

DOI

10.65712/tmj.test000419

Tranexamic acid and in-hospital mortality in adults with type 2 diabetes: A case series

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around tranexamic acid varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: in-hospital mortality occurred in 6% of the intervention group versus 19% of controls. Serious adverse events were rare and similar between groups. Conclusion: Residual confounding cannot be excluded.

Introduction

in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes. The cost of in-hospital mortality to health systems is substantial.

Guidelines make only a weak recommendation on tranexamic acid. The cost of in-hospital mortality to health systems is substantial.

Materials and Methods

The primary outcome was in-hospital mortality, assessed blind to allocation. We conducted a case series across 1 centres between 2019 and 2022. We conducted a case series across 8 centres between 2016 and 2024.

Analyses were adjusted for age, sex and baseline severity. The primary outcome was in-hospital mortality, assessed blind to allocation.

Analyses were adjusted for age, sex and baseline severity. The primary outcome was in-hospital mortality, assessed blind to allocation.

Results

Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.73 (95% CI 0.43 to 0.80).

Effects were consistent across prespecified subgroups. 4412 participants were included (median age 69 years). 518 participants were included (median age 55 years).

GroupnEventsRate %
Intervention2317433.1
Centre B971056.3
Age ≥ 65530781.9
Centre A36211920.1
Centre B8301640.8
Age < 65224862.4
Intervention977636.3
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Kaplan–Meier curve for in-hospital mortality
Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.

Effects were consistent across prespecified subgroups. 3132 participants were included (median age 30 years). Serious adverse events were rare and similar between groups.

Discussion

Implementation will depend on staffing, cost and local protocols. Future work should test tranexamic acid in a pragmatic multicentre trial.

Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.

Conclusions

Tranexamic acid is a reasonable option for adults with type 2 diabetes to improve in-hospital mortality.

References

1. Okafor F, Tanaka D, et al. Home-based cardiac rehabilitation and health-related quality of life. BMJ. 2024;311(1):777-1703.

2. Silva E, Schmidt M, et al. Tranexamic acid and post-operative delirium. JAMA. 2011;325(7):303-986.

3. Andersen C, Novak M, et al. Machine-learning triage and time to diagnosis. Crit Care Med. 2017;86(2):636-982.

4. Rahman M, Kaur K, et al. SGLT2 inhibitors and glycaemic control. Lancet. 2012;134(11):658-1289.

5. Ibrahim E, Ibrahim N, et al. An enhanced recovery pathway and ventilator-free days. Eur Heart J. 2022;208(4):335-910.

6. Yilmaz K, Okafor Q, et al. An antibiotic stewardship programme and chronic pain scores. BMC Med. 2019;390(6):232-1396.

7. Larsen S, Nasser D, et al. Continuous glucose monitoring and medication adherence. Eur Heart J. 2012;189(11):151-1592.

8. Tanaka U, Ahmed K, et al. A sepsis alert system and glycaemic control. Crit Care Med. 2024;210(12):689-1782.

Appendices

Ethics approval: IRB-9729.